Rolke James 4
4 · LA JOLLA PHARMACEUTICAL CO · Filed Mar 3, 2020
Insider Transaction Report
Form 4
Rolke James
Chief Scientific Officer
Transactions
- Award
Stock Option (Right to Buy)
2020-02-28+142→ 142 totalExercise: $6.80Exp: 2030-02-28→ Common Stock (142 underlying) - Award
Common Stock
2020-02-28$5.78/sh+142$821→ 80,677 total
Footnotes (2)
- [F1]These shares were acquired on 02/28/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- [F2]The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years.